Press Releases
Jan. 30, 2018 Bioasis Announces Filing of Quarterly Financial Statements and MD&A
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and… Read more »
Jan. 8, 2018 updated: Bioasis to Present at the 2018 Biotech Showcase Annual Conference
Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Dec. 4, 2017 Bioasis Implements Transition Plan for Its Board of Directors
Company intends to selectively replace outgoing directors with new, highly qualified, independent candidates
Oct. 10, 2017 Bioasis Establishes U.S. Presence with Office in Connecticut
The Company also launches new website bioasis.us
Oct. 2, 2017 biOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board Advisor
Lowe brings extensive experience serving as an executive and board member for early, research-stage biotechnology companies
Sep. 21, 2017 biOasis Announces Voting Results for 2017 Annual Meeting
The Company welcomes new board members Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan
Sep. 18, 2017 biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member
Additional Board & Leadership Team Changes Also Announced
Sep. 7, 2017 biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform
Distinguished Research & Development Scientists Prof. John H. Krystal, M.D., Jeffrey L. Cummings, M.D. and John P. Wikswo, Jr., Ph.D. Appointed as Inaugural Members World-renowned Psychiatrist Dr. Krystal will Serve as Chair of the SAB
Aug. 28, 2017 biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders
New Board nominees include accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., CEO at True North Therapeutics; Deborah Rathjen, Ph.D., CEO & Managing Director of Bionomics; and Maha Radhakrishnan, M.D., SVP & Head of World Wide Medical at Bioverativ Therapeutics Inc. biOasis Founder Mr. Rob Hutchison will step down as Chairman of the Board on Dec. 31, 2017
Aug. 21, 2017 biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer
Williams bring significant experience in working with both large, multinational pharmaceutical companies & start-up biotechnology alliances